Description
Tevosol has developed and tested a normothermic organ perfusion system for preserving and assessing organs recovered for transplant. This project will build on the previous Device Definition work to engineer subsystem-level prototypes to de…
Amendment chain · 2 entries
Each notch is one published row for this agreement: #0 is the original (placed at its start date) and each later notch is an amendment (placed at its amendment date). The height is the agreement's total value as of that row — the source column is cumulative, not a change amount — so the line reads as the commitment over time and the right-most notch is the current commitment shown in the header. For this agreement: $232,500 at start, $232,500 after amendment #1 (+$0).
- #02018-08-01$232,500
- #12019-02-13$232,500
| Row | Date | Total value as of row | Change vs previous | Description on this row |
|---|---|---|---|---|
| #0 original | 2018-08-01(start date) | $232,500 | — | Tevosol has developed and tested a normothermic organ perfusion system for preserving and assessing organs rec… |
| #1 amendment | 2019-02-13 | $232,500 | +$0 | Tevosol has developed and tested a normothermic organ perfusion system for preserving and assessing organs rec… |
Related records · 6
Records are related by an explicit link in the data, stated for each group below — never by text similarity. Values are each agreement's current commitment (latest amendment).
Other current agreements for the same recipient (business number 821124799)
| Ref | Department · program | Current value | FY |
|---|---|---|---|
| 172-2019-2020-Q2-932836 | National Research Council Canada | Conseil national de recherches Canada · Industrial Research Assistance Program – Contributions to Firms | $440,000 | FY2020 |
Other recipients funded under "Industrial Research Assistance Program – Contributions to Firms" by National Research Council Canada | Conseil national de recherches Canada (most recent first)
| Ref | Recipient | Fiscal year | Current value | FY |
|---|---|---|---|---|
| 172-2025-2026-Q2-1034675 | Mediphage Bioceuticals, Inc. | FY2027 | $63,380 | FY2027 |
| 172-2025-2026-Q3-1037522 | OBKIO INC. | FY2026 | $50,000 | FY2026 |
| 172-2025-2026-Q3-1037889 | SERVICES DE DEVELOPPEMENT PROFESSIONELS SDP INC | FY2026 | $25,000 | FY2026 |
| 172-2025-2026-Q2-1034040 | Griffith Foods Limited | FY2026 | $54,880 | FY2026 |
| 172-2025-2026-Q3-1037273 | Apollo Machine & Welding Ltd. | FY2026 | $230,000 | FY2026 |
Cite as: Glassbox record view · Federal grants & contributions · 172-2018-2019-Q2-911378 · retrieved 2026-11-15.